Figure 2.

Atorvastatin (Ator), but not pravastatin (Prava), inhibited mTOR activation in cardiac myocytes. NMVMs were incubated with either 1 or 10 μM Ator, Prava, or vehicle for 48 h. A) Total lysates underwent immunoblot analysis. B) Both statins did not alter total or activated mTOR^Ser65 protein expression. C–F) The downstream targets of activated mTOR, p70 S6 (C, D), and S6 RP (E, F) were up-regulated in Prava-treated cells but decreased in Ator-treated cells. G) Both statins increased 4E-BP1^Ser65 expression. Tubulin was used as loading control. B–F) Densitometric analysis of representative immunoblot bands (n = 3 wells/treatment, each experiment repeated 3 times). Means ± sem. *P < 0.05, *P < 0.01, *P < 0.001, *P < 0.0001 (1-way ANOVA with Tukey’s post hoc comparison).